12/15/2011

The FDA approved ViroPharma's supplemental new-drug application to include clinical efficacy and safety data
on the label of Vancocin, which treats Clostridium difficile infection. ViroPharma says the approval
makes the drug eligible for three years of market protection.

Related Summaries